Trial Profile
A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2021
Price :
$35
*
At a glance
- Drugs PIM 447 (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Adverse reactions
- Sponsors Novartis Pharma KK; Novartis Pharmaceuticals
- 01 Jun 2021 Results evaluating the safety,tolerability,preliminary efficacy,pharmacokinetic and pharmacodynamic profiles of PIM447 in Japanese patients with relapsed and/or refractory MM published in the International Journal of Hematology
- 22 Aug 2017 Status changed from active no longer recruiting to discontinued due to clinical development strategy to prioritize combination therapies and other indications.
- 19 May 2016 Status changed from recruiting to active, no longer recruiting.